Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

53612_S117

— · cohortMD2

7b20515e-1547-5f2b-862d-15b527fd7b30

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD2
subtype
cohortMD2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.590
  • INTERFERON_GAMMA_RESPONSE+0.500
  • INTERFERON_ALPHA_RESPONSE+0.470
  • IL6_JAK_STAT3_SIGNALING+0.420
  • INFLAMMATORY_RESPONSE+0.360
  • COMPLEMENT+0.350
  • IL2_STAT5_SIGNALING+0.310
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
  • KRAS_SIGNALING_UP+0.270
  • TNFA_SIGNALING_VIA_NFKB+0.210

Top 10 suppressed

  • GLYCOLYSIS-0.400
  • MYC_TARGETS_V2-0.340
  • ESTROGEN_RESPONSE_EARLY-0.330
  • CHOLESTEROL_HOMEOSTASIS-0.270
  • ESTROGEN_RESPONSE_LATE-0.270
  • FATTY_ACID_METABOLISM-0.250
  • NOTCH_SIGNALING-0.240
  • ANDROGEN_RESPONSE-0.210
  • PEROXISOME-0.200
  • WNT_BETA_CATENIN_SIGNALING-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518332
breast-umap@18
—D0.889
2C3N-00433
lung-landscapes@6
—cohortMD20.881
3DRR168577
bladder-landscape@3
——0.857
4767fc312-2c66-43f7-b78e-bf79e03e3a0a
colon-landscapes@1
——0.855
5SRR8518387
breast-umap@18
—D0.845
6SRR8518127
breast-umap@18
—D0.844
7SRR8613789
breast-umap@18
—A0.841
8SRR8518454
breast-umap@18
—D0.838
9SRR8613774
breast-umap@18
—D0.829
10BSR_02_0049_A5_S69
breast-umap@18
—D0.829

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.590Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.500Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.470Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.420Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.360Idelalisib— uncovered
COMPLEMENT0.350Inavolisib— uncovered
IL2_STAT5_SIGNALING0.310Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.290Inavolisib— uncovered
KRAS_SIGNALING_UP0.270Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.210Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.200Inavolisib— uncovered
APOPTOSIS0.180Idelalisib— uncovered
TGF_BETA_SIGNALING0.170Inavolisib— uncovered
PANCREAS_BETA_CELLS0.110Cobimetinib— uncovered
APICAL_JUNCTION0.080Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.080Inavolisib— uncovered
UV_RESPONSE_DN0.080Inavolisib— uncovered
APICAL_SURFACE0.060Temsirolimus— uncovered
MYOGENESIS0.060Inavolisib— uncovered
COAGULATION0.050Binimetinib— uncovered